Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1083 participants.

Also called NCT06153693

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,083 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06153693
Other papers using this trial's data
  • Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial JAMA, 2025-08-05 DOI, PubMed 40587141, PMC12210145 PubMed links an erratum for this paper. Erratum: PMID 41525067 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Bulgaria, Canada, France, Germany, Italy, Netherlands, Poland, Puerto Rico, Romania, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06153693. Randomized; double masking; primary purpose treatment. Start 2023-11-22 (actual); primary completion 2024-12-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
Condition
Hypertension
Intervention (Drug)
Placebo
Intervention (Drug)
lorundrostat Dose 1
Intervention (Drug)
lorundrostat Dose 2
Lead sponsor
Mineralys Therapeutics Inc. (class: industry)

Record details

Record id
cardio:ct-nct06153693
Content hash
2a0ac53faff92a8d586006a73e9d9f4e8d42b14d5072bc2b881a3103a674b107